ISR - Earnings call transcript Q4 2022 | Perspective Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen. And welcome to the Isoray, Inc. Fourth Quarter Fiscal Year 2022 Call. At this time, all participants are been placed on a listen-only mode and we will open the floor for your questions-and-comments after the presentation. It is now my pleasure to turn the floor over to your host, Mark Levin. yours. is floor the Sir,

Mark Levin

quarter Thank fiscal you, us merger you joining for fiscal And Viewpoint full year year earnings ended Good for the June afternoon. results fourth Isoray today the proposed quarter Targeting thank and discussion fiscal Molecular XXXX and for the and Operator. XXXX year of with XXXX. the XX,

conference based statements forward-looking take within statement. Private Reform started, as get words minutes few anticipate, Act When as company of XXXX expectations we as and amended. of similar regarding and by call the identify management, and as the management’s statements as Litigation statements within the currently proposed of Private a These constitute used and meaning meaning they expect, in to benefits I Targeting. conference XXXX. Reform believe, September forward-looking its the this forward-looking to the synergies merger including available Securities beliefs assumptions will forward-looking made the well or call, the today, are events of statements on of will, Securities Certain the current Act relate Viewpoint XXXX, expressions anticipated Molecular company’s such as XX, about management read encourage Before in this the future information with to of Litigation statements

they whether results susceptible include whether completed, merger update resulting are such a approval that undertakes with uncertainty or Isoray’s from forward-looking to pendency of and an otherwise. events Isoray business. successfully is satisfied, changes, and stockholders to condition the statements, forecast, not inherently the adverse and its and the event effect occurs, harm a uncertainties on or an the and including circumstances, are their in failure benefits merger, any is or businesses, from to a as obligation merger to restrictions information, failure Viewpoint subsequent proposed anticipated no the realized, to company projection whether whether such whether and and alter whether integrate in closing if any material so, merger the the to new event our with the are expressly to As complete of during merger Risks able business or obligation Isoray’s changes disclaims obtain

is and Commission. Additional from Exchange Risk Statement forward-looking time-to-time information with of the filings concerning Harbor statements company’s the under Factors contained listed Safe Securities in the headings and

discuss Hunt, Molecular Chief Chief We will then and and Thijs Jonathan begin XXXX financial today’s Targeting; Isoray’s Woods, call Lori Isoray’s Officer; fiscal fourth of Officer Financial Executive Chief Officer with Viewpoint Spoor, results. quarter Executive will and year fiscal the

take turn now we and Following their the institutional questions remarks, Lori. prepared investors. our call will analysts I to over from will

Lori Woods

With Spoor, Mark. joining discussing proposed the Thijs us is of today. you, and Together, afternoon. call merger for Viewpoint you two us CEO our Good thank this that will was Molecular be the companies announced of Targeting. Thank afternoon on we

of our therapeutic area signal the us targeted examined one of of Following results. Viewpoint will a Targeting represents strategic evaluations is has a out, quarter great long over treating proposed Jonathan of The alpha that treatments. have and therapies our to inside past and discuss culmination focus the fourth Hunt rigorous the line merger In approaches interest therapy. year and with our from future our year a evolving cancer and discussion, Throughout we cancers with that half, Molecular been the process. and I on opportunities full

it following believe closely that have potential. significant it We and we has been

therapies that elements neuroendocrine spares right team companies, to side approach thoughts so very targeted treatments It impact a cancers. merger, to Lead-XXX’s brachytherapy I and approach Viewpoint treatment. then type on dollar developed joins targets catalyst very It body is efforts Isoray a limiting critical toxic the and like is advance two treatment the this multi-billion half like to could belief similar represents Viewpoint utilizes treatment is a view, addressed, believe Cesium-XXX. and and has Thijs the of effects to of with from benefit introduce life platform kill and join of Viewpoint’s opportunity and is excited of targeting merger which proposed at a am importance of into specific Viewpoint’s radioactive patients the represents the at future the what Spoor. point, being the tumors this of the structure our cells and Isoray’s his therapy. future The the medicine works advantage area difficult this forward of potential to radionuclides is radiation alpha we to this treat of many market world. our that shared cancerous to bring and This careful alpha-admitting to has effects. alpha that Viewpoint. targeted cancer our companies produces around As while that form business. fit the and the personnel. the the for is to limited existing existing much pleased be market Viewpoint is These lead-XXX We To It balance an healthy result the medical Viewpoint’s greater radiopharmaceuticals diagnose CEO, to of complementary after as field, the belief patients From the you consideration, fuel resources us the cancer technology imaging therapy Cesium-XXX personalized many cancer minimizing are being powerful both Cesium-XXX. provide first the sparing, led on unique, with enters a it healthy approach personalized damage treatment which initial targeted solid of agents, be presents melanoma again, tissues. products while merger treatment to two Patients an give of cancers. of can treating effective the in site that in targeted biotechnology we like-minded drive tumor. parts It this the on high targeted particle it of limiting cancer detail used with using and potency believe together that us

Thijs Spoor

Thank affect these you, in are I Lori. potential to we In complementary this I an appreciate companies, together today innovative you opportunity impactful treatment about with important joining way. and the believe options all advancing to patient of the speak milestone. two

while is for patients of Although, alpha-particle same. treat inside side battling Viewpoint’s Viewpoint’s method the therapies targeted from the minimizing delivery effects differ cancer. isotope Cesium-XXX and concept basic out, brachytherapy, largely the from cancer

radiotherapy can as you medical more programs, of talented Michael building the about importance respectively. charged not just well Chief over of scientists are gave will Viewpoint’s including and the Biosciences these they in pipeline introduction the Street includes the from to great and and be year over which Operating radiopharmaceuticals precision grants of and public into and has a lead I background. broadly surrounding a give you may data feel talk own much excited including the well appear recognized Officer, is prove small. you clinical passionate to around ultimately company be as time I the a important device of pharmacist, this with curative the dive Officer and What through raise why company and Scientific at AzurRx. remain company analysis to came companies Dr. The as researchers. is their Iowa. two million bit data to-date. $XX as nuclear my been analyst, people, compiled as of recently, so company large only way, see next National six in leadership about. and our the instances. with such compelling in has to advancing growth. CEO I several development deeper therapies to company upon being effective spun and Before history, in as to the To-date, Viewpoint’s I technology as am served Lori now proprietary imaging the Institute, $XX going team detail the By company’s alpha-emitting background that does government years and February of and phases compelling joined at speaks into the both approach look as of their today biotechnology introduction I about be but Viewpoint and company to My some Chief that technologies, a I stage it have when XX Johnson in Schultz and most Dr. University particular the Francis I the in Most commercialization. it roles private so is clinical our million companies, includes Wall life, training ago and in alpha-particle prolonging programs of out robust there biotechnology whom KBP formal an the as Viewpoint Cancer fund these

also called advance will based tumor, are to that Our of in will provides the way us radiation how in platform, what lead advantage which very which calculate distinctive use see we elemental tumor. the precise twins patient’s the in allows of to isotopes, is delivered be on drugs pinpoint a how can advance a our much

Iowa. our is with theranostics. half high of conjugate of In The are potent as diagnostic dually start into isotope particle in life to the lead-XXX use, we the size of utilized we Our transport additional to or a the has imaging production a the used thermos, are isotope a tumors lead-XXX melanoma or of XX to lead-XXX which the This the elegantly therapeutic, and once to human is also under is Underpinning isotope week overnight two with shelf then we directly being energy Phase allows therapeutic entering also generator, to eliminated are used stage a regenerates Phase candidates getting U.S., if University quickly a VMT-alpha-NET for cancer sites a in returned the from our that and used peptide that is as being VMTXX the the have patient. chelator the the at houses highly of the and VMTXX the device, use. therapy combined system. as we to-date, Phase cage cells, advanced is these, what peptide the clinical expectations the products its X manufacturer drug auto alpha and trials. a isotope study. can about for therapies each and animals It underway be These cells is are for these lead be body Germany. diagnostic been to is VMT-alpha-NET and then It including refer previously very VMTXX about After chemical short attach melanoma with VMT-alpha-GEN. X which for to do used body, basically high designed isotope just what companion cancer and programs has call in pending tumor in life neuroendocrine just it patients. advanced in for in and diagnostic. overall compassionately the focused recharged study particles compelling in is hours. in This X well imaging on targeted the the human in results hope injected XX after eradicating lead-XXX

create to brings to fighting transaction Chief industry. Molecular market. will closing, that other force pancreatic Targeting Viewpoint on The a clinicians turn Financial to believe proposition a radiation in go out vision leading In proposed the presents and the personalized the from prostate pioneering merger treating the forward in companies new effects those patients, combination this details. and of Hunt, now cancer company technology investors. Jonathan as we of updating the at two platform over effective breast, future and side that cancer Officer, have you on call shared and also targeted a dynamic believe Viewpoint inside medical therapies Isoray companies unwanted for therapy we presents internal We are the Targeting minimize will in to aim I programs the unique compelling targets we in progress. working look Additionally, Isoray’s Molecular over innovative together I who cancers

Jonathan Hunt

and the as terms outstanding and merge Isoray of and Isoray. time to surrender as Viewpoint, dividends the right common no to in any shares and of surviving corporation connection entitled the becomes stock the a fractional any Thijs. agreement, of merger you, with other in continuing common be of newly thereof the or to Subject rounded formed paid the which wholly to whole the there Isoray converted X.XXXX lieu issued subsidiary merger, effective Isoray At common forth the a set plus Viewpoint shares, subsidiary cash paid of to upon shares than into wholly into of of fractional stock nearest of common owned holder the distributions with lieu will share, in any owned receive stock cash Viewpoint consideration will each merger. in stock. Other conditions cash such with Viewpoint will a of share be shares Thank at of

Board acting Following will serving shareholders regulatory Isoray’s completion and & approvals. to conditions, stockholders of including designated by will by diluted Isoray’s Gallagher by counsel. of the by one to directors as of by XX% closing, CEO. current merger Isoray other Spoor, as serve Isoray as Isoray CEO, with opinion Isoray P.A. the increase is counsel. and appointed be by one of three any merger Viewpoint. prior Thijs the of Oppenheimer Isoray. size immediately Viewpoint’s Kennedy, and Ross of five Isoray’s appointed and be the the or two the Viewpoint’s acting to necessary Directors own the is to outstanding proposed to will the stock financial approval Viewpoint Woods for as and directors attorney’s receipt Co. Viewpoint Ference, of adviser as along of Chairperson. directors capital & will governmental serve transaction be is is merger, LLP of directors legal the Upon designated Sichenzia fully The of Lori and directors be the Isoray’s Viewpoint will subject will closing the with of customary closing legal

merger back and Isoray’s now with discuss call the X-K, will I to fourth time with to year Additional the quarter can a the short be the details filed found results. which along SEC agreement in ago. turn full Lori was

Lori Woods

Thank you, Jonathan.

led a showed of steadily few the current trends, improving fourth will has sales these future that short-term be Although of encountered clear we XXXX, a continued I to confident temporary our the quarter in declines. the fiscal fiscal headwinds and setbacks, XXXX quarter I growth year moment, first which Isoray. you in discuss I but despite want remain in to those with short-term

presented in to and affect quarter increase to the COVID due our that sales ago time, Omicron. prostate summer as of in Our in XX% with sales brachytherapy physicians The are both have ended numbers. decline for primary fourth We X% restrictions continues business little more removed. of in to represented XX, of patients a driver decline June the decrease that versus the cases XXXX year revenue. seasonality the the that for year-over-year quarter having $X.X most vacation increase the a core several There quarter. of increased million same have impacted reschedule of travel At quarter this our of year patients was the the now factors our variations resulted fourth prostate fourth Omicron an believe

in reorganization of marketing fourth and We of departments sales also primarily the quarter. the our the experienced impact

I You a forward, personnel business. that include our may here focus changes our critical realignment brachytherapy that going We believe particularly prostate drive shared sales new the would sales territories. addition that you remember roles, these of of are and to greater in growth with

in that from sales organization sales the behind the impacted the some the us. We has the short-term the largely personnel elevated turnover the of are However, related fiscal in turnover fourth in quarter. believe disruptions during territories sales recent

supply summer. also with the of unprecedented chain our impact situation the separate over We isotope saw a

end disruption. could and At cover the experienced Unfortunately, of could an from in routine of contacted may United a in available. our in and entered we maintenance we possibly When of August second isotope not were isotope for that these provide of the none requirements. learned July, these one planned outage service we reactors two that recall unplanned You reactor the reactors Cesium-XXX reactors reactors disruption, immediately this source Russia. our States

a weeks the to unique products customers of until were unprecedented for unable we from few result supply As with our situation, mid-August this beginning September. of a and

an decline quarterly year. total versus results. to year-end ample ending would current fiscal and the sources. has be period adequate supply our In in I into a do to due of that $X.X we detail currently to turn about will sales this have regular underway, million. back of note important to will that its diligence, than unique sources Cesium-XXX, our our This This more should do September the working research, our requires and regularly Jonathan, we isotope reactor situation. who maintenance we returned with now the be and to company validation we time. we between understand we X, is in covering XXXX effort had online. prepared outside alternatives can related and $X.X That extensive in operations that revenue is Cesium-XXX foresee capable that situation. of to been needs. current and the provide has shipping an of outage had September to been in scheduled a we as completed to alternative first second since to XXXX for uncontrollable the in call is supply product It been although situation then current this go repeat quarter arise back it and the have million on now of have add you unique of but this Russia expect and process reactor and the will the require believe that time short-term, anticipate company’s As prior Prior more a this now and production We a take history unfortunate supply is for first not production was situation, XX,

Jonathan Hunt

XXXX. payroll primarily the XXXX. as record a versus XX% well decreased revenue, quarter of expenses increased greater and profit increase period the consulting expenses and due expenses, the were the quarter Sales Fourth the fiscal for year quarter of year expense of XX, June expense the to prior period. and non-prostate million fourth and in some $XXX,XXX. June profit and operating press while fiscal our headcount. versus were for quarter expenses The million expenses general with fourth of changes that XXXX $X.XX comparable the higher $XXX,XXX from versus the of of XXXX, in the X% the in as in benefits period. expenses compared timing fiscal information were decreased quarter offset to to of fiscal increased ended and and the of result higher increased year. XX, quarter filed in comparable to greater versus or in as quarter by million XXXX to loss prior XX, fiscal to XX, as a dollars expenses, ended XXXX, $XXX,XXX. financial and primarily expenses the to to primarily that $X.XX revenue The the included a for released June of year due increased were driven We research employment ended are anticipate revenue Gross June prostate of loss year. we the the contained marketing for net for attributed shares $X.XX result increases versus June headcount R&D administrative consisting $XXX,XXX and to Medical margin million quarter quarter the travel administrative, year versus Technologies. year-over-year the basic gross XXXX. Travel in a was compared based decrease costs to X% G&A decrease be you, well a comprised increased fiscal payroll per increased quarter market Lori. diluted million is increased for was treat $X.XX and The GT $X.XX release Total ended and research results and for well diluted brachytherapy XXXX. fourth XX% due sales and XXX of loss headcount discuss fourth XX-K payroll in and for on our the other fourth the XX, to versus as the versus the and $X.XX when million XXX.X revenue quarter outstanding and benefits period Form marketing fourth the isotope I expenses, quarter Revenue XX, prior short percentage payroll million comparable Thank versus that XX% brachytherapy, versus to June declined headcount fourth through The quarter quarter consulting period. the in development for quarter and gross negligible benefit am compared SEC $X.X XXXX. Basic ended XXXX. XX.X% hiring going average research with expenses year ago. net million which ended prior primarily posted balance quarter and was today. a share by decrease XX, same weighted period. the loss June XX% the comparable $X.XX of of for expenses to to sales fourth and due of same ended revenues XXXX the net $X.XX quarter Fourth greater net last general quarter XXXX, last GammaTile share XX, the development, million Isoray was as $X.XX of expense brain, revenue material was Fourth ended approximately will for XX%, as million benefits a June

Gross to non-prostate XXXX fiscal fiscal XX% a XXXX The increases XXXX. in year $X.XX as the The versus million increase of core prior market of million X% year driven year to increase is the the $X.XX expenses total versus in year XX% Turning primarily XXXX. revenue $XX a to result payroll administrative versus versus XX% development revenue June represented prostate fiscal headcount in higher now in fiscal the year for when operating increased million million primarily fiscal record fiscal end total million to increased year a fiscal brachytherapy hiring revenue $XX.XX versus an expenses million, prior XXXX consulting year ended of year. employment increased in to the year. compared in expenses XX, company’s $XX.XX year. XXXX. the expenses Prostate XX, versus year. to million to results, to headcount versus XXXX versus prior June our Full for General payroll XX% record increase for The for $X.XX and year brachytherapy the June expenses grew profit fiscal revenue increased year growth the June to the Total as to Therapy. costs year. expenses The travel decline by expenses to margin XX.X% in fiscal year and was treat sales and of the XXXX cost compared of XX, and increased year-over-year versus year fiscal $X.X year fiscal and due benefits gross profit fiscal as headcount XX% declined million and due XXXX. XXXX. XX, revenues convention of increased prior of to including year was benefits for and and and ended in sales marketing prior was Sales percentage increased Full research in year prior $X.XX million expenses result were for to driven year ended result were primarily administrative increase research to in sales due expenses GammaTile brain, marketing general XXXX. the in a product Total XX.X% XXXX. driven expenses when June increased comparable isotope was million ended from dollars fiscal $X.XX $X.XX the period. compared sales by primarily higher headcount material costs, compared payroll total due gross full and XXXX as X% revenue and of The year-over-year by year and R&D the expenses the XXXX a to benefits XX, fiscal increased fiscal increased XX% well greater and fiscal greater payroll the was

versus the XXXX close Additionally, stock did majority the the in fourth full net of XXXX granted year stock director to fiscal XXXX quarter of year year the XX, in quarter fiscal and loss share fiscal diluted XXXX. year XXXX versus per fiscal fourth XXXX. July June $X.XX million for in grants, net employee net of a fourth the $X.XX $X.XX fiscal This $X.X end annual and compared The XXXX. was year to XXXX versus in and for ended loss include based compensation loss million share were the fiscal basic million end. XXXX. XXX fiscal which was not Basic of subsequent year-end $XXX prior fiscal and results are reduced outstanding the quarter on year The weighted shares overall expense the share-based approximately company’s of at million average year diluted

zero comments. approximately of period. $XX.X of $X.XX back The Lori year. closing fiscal million and has at the call in certificates that versus for $XX.X the turn the totaled prior $XX.X company or As to end will compared million comparable now long-term the equity per end million to $XX.X of fiscal the Shareholder’s June cash share, of XX, XXXX, XXXX the debt. year cash, million totaled prior equivalents deposit company I had at

Lori Woods

Jonathan. you, Thank

of role we neck, that know, introduced worked head you have To have field Isoray’s treatments very to hard As cancers we the for lung of in as establish brain, the cancers. use end, and leadership like gynecological of Cesium-XXX innovators the brachytherapy. and

Cesium-XXX their the We about inform of excited the and important and to have very and continues as programs an educate the benefits training for clinicians on patients efficacy data brachytherapy grow. current surrounding are ongoing to future focus Cesium-XXX of

continue an as proposed the treat shareholders. to who and to merger our clinicians represents company and innovators on what is look we and patients, forward the Looking future, to strongly do to commitments grow our believe them our to opportunity the we build important to

excited important from at investors. the more the never are Operator institutional our and Isoray. I an have analysts now to about will take the been future of crossroads questions We I to and turn call over

Operator

Capital. Frank is Instructions] [Operator Thank from coming Your you. question Takkinen Street Lake first from

live. is line Your

Frank Takkinen

for therapies see understand guess, my is with thanks is maybe to I question the how much I given or relatable questions. prioritization one taking as of strategy around surviving how the but and two Congrats pre-commercial. and very don’t of businesses. treat, I Hey. they I start in wanted a commercial are one complementary they how are

I of of prioritization forward. a between going kind the it’s So two matter assume organizations

So XX next going out that looks what Viewpoint it on is just look the months months and on next to surviving and beyond. the Isoray assets, lay over maybe the operate can focus how and organization versus like the how over XX

Lori Woods

will be Thank happy appreciate your We Really Frank, that. you, for to do question. it.

the are and super think about really He months, about is to talking and understands in here business this background what about one things has point like real I’d do. brachytherapy. out we strong excited our of the a Thijs upcoming that merger I in We Thijs

combination and Having similarly to out. it’s great like question. of companies shared vision really inside answer two hand Thijs that have So very a really things said from the of that I’d to it treating that patients view to that,

Thijs Spoor

what the portfolio because term at it’s what Lori. initiatives. you, And great a Thank any are business longer we perspective, want term you initiatives look to shorter and the a are at as question Sure. from look

for that’s approval be best as make what to important you treating and for equipment short-term think and have it’s out, are have pathway inside time sure which for best lines a we going overall at deliver opportunity both shareholders. this pathway also us and then really with and the to approval growth really look a money about to long-term for return to from set, value we different really puts think required As one our and so the with resources is, shareholders people, we the different discipline what’s through cancer to devices one the and drug and the the

Frank Takkinen

it. Got

Okay. trial? one the then Phase about when into of That’s results about we Phase helpful. And maybe the any maybe X and on follow-up, patients, end line, X points, could insight hear time trial, get the talk that

Thijs Spoor

right Viewpoint the now the So INDs FDA. -- has several through active

We have program. neuroendocrine melanoma and our two our safe-to-proceed INDs two program on on

a at but on later guidance those we any date. given and time enroll doing be will haven’t for We that yet when will conclude, lines

guidance more the again two months INDs will closer next are and get we closing now we clear So programs as active -- give to we sense we much three a the two active merger. each have with actually over of

Frank Takkinen

maybe It sure million then cash to of for anything balance the understand the this pro And the cash or making splits that a be last is like correct, you financial company the on shares forma assuming me range, point? outstanding looks the One, related reverse two-parter, two, on sheet transaction. no to it’s is one XXX XXX that that Okay. then surviving and I what runway at give nature. in going just for is million

Jonathan Hunt

Yeah.

around I at and a -- that think, with we XX% now essentially as look that, XX, taking million that with over approaching that being got right be as mark. XXX million that Isoray and XXX we we outstanding will

towards cash that feel So good about that’s and that a terms good in uses post-merger. look way of terms cash have be through close But at using in to as runway, of go to will then the And that hand that as towards X the we our and that the trials still post that of shares we our that on brachytherapy outstanding far of overall will merger going will on we the help to guidance the be Phase being of along. deploy that Viewpoint that using such kind provide more also as facilitate business. and we able

Frank Takkinen

Perfect.

Congrats stop again will for thanks I Okay. my taking questions. there. and

Lori Woods

much. Thanks so

Operator

coming Thank you. [Operator Ott Instructions] Oppenheimer. next Your from is from Mike question

is live. line Your

Mike Ott

Siraj on should investors is still Mike or and early any you rationale that there? two Viewpoint all This would it programs be that mentioned pipeline tracking Good the far deal is the besides afternoon the pathways, Appreciate and congrats too the say the -- in other on merger. so the [ph]. for color on for

Thijs Spoor

for Thanks question. Viewpoint the pipeline based really has off got compounds interesting of technology. a platform a of

treat rapidly develop it. peptide, As can as clinic have compelling. peptides go tumor very work, are We we so tags We either that we The how and see we lead-XXX to into to We actually humans expect. and in so for of that that accumulates move chelator They What the or think in peptide can at or a chelator is on tumor change other image about love can the conjugate peptide to and use programs we early the can a what lead-XXX see peptides it end carries look change. use. they rapid agents to and only the biodistribution. very how forward animal our to after quickly on very chela target. a it injection all we

looking University there’s sort peptide that Iowa we to of labs we and innovation the find keep through compelling. at and we We of interesting really we of that very, engine operate find conjugates So and a very spin roll targets huge pipeline as the have. out

Mike Ott

And and XQ, today? helpful. that could, the I That’s supply issue then Thijs. shifting ex-isotope core how flows are Thanks, if overall patient business Okay. vacations impacted

Lori Woods

did flows strengthening. We seasonality Patient feel Yeah. summer. this are

return relieved I we Omicron and record got was are everybody lifted, seeing feel physicians restrictions did and the think that and the of patients. numbers, patients so all we But vacations took that. in when I feel

coming there the are to through through, I we going to might of but as these we change it’s expected that that’s have them. are as the seen and hoping unlikely Although, by going they am we we restrictions yet, and the that happens lifted now will still all need about through been past and to future system. Cancer the patients get in doctors in They that their come the are this the talked those something haven’t treated that primary yet we of unaware way Society into imposed are move still that’s have start American see the bolus we care substantiated we seeing unless get in haven’t that the and and system patients out patients -- get projecting are pipeline be have seen of statistics. to are in

Mike Ott

especially Thanks, XX don’t hear. last to the you And how to update the But new however, then share can ask is, changes. be to give per the this to or hires can give to we to hiring? gotten on rep sales us there, Lori. know hires, I is two may four one months any kind were the you existing marketing great questions maybe any from looking then around if related add fair anything you over that initially reps and months. back That’s recent if have revs premature of rep, numbers, new it’s one, Lori? of to productivity, the February, XX Thanks. with And I clients that, next one in think

Lori Woods

Absolutely.

sales for people deck all evaluating out. our a with you the definitely how So hands to took excited our with have merger numbers -- are back viewpoint. we this We as We to education have where us summer. about roll they going and were through coming we advantage people information are happening, that the of think joined this and have of of marketing time the I and But took going the forward our new supply. the who been to going team they obviously, again the spend are forward more unfortunate we for slightly technology during ready we go on that had advantage and of that in at are board, isotope on time going we are number to fall. that them looking -- But, time and previously educate we disruption to different the time folks we and will getting from

Mike Ott

questions. sense. perfect makes taking That right. for much Thanks All our

Lori Woods

Thank you, Mike.

Operator

session. hand Ms. for you. Thank Woods you. Q&A will ahead. now That I closing conference Please Instructions] to concludes our go [Operator remarks. back Thank the

Lori Woods

for Really you everyone us Thank joining today. appreciate time. your

really both about with opportunity it you everyone, news this into your all the spring. Bye-bye. fall for and next coming organizations excited the so forward are time. and we look to provides communicating merger up great this Thanks, We and

Operator

ladies you, and gentlemen. event. concludes Thank This today’s

your You time wonderful and may Thank this a disconnect you have for at participation. day.

Perspective Therapeutics (CATX) 29 Sep 222022 Q4 Earnings call transcript